3 Stocks Boosting The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 29 points (0.2%) at 17,012 as of Tuesday, July 29, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,550 issues advancing vs. 1,408 declining with 169 unchanged.

The Drugs industry currently sits up 1.0% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Pharmacyclics ( PCYC), up 11.9%, United Therapeutics ( UTHR), up 7.5%, Regeneron Pharmaceuticals ( REGN), up 1.2%, Sanofi ( SNY), up 1.0% and Novo Nordisk A/S ( NVO), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Bristol-Myers Squibb Company ( BMY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Bristol-Myers Squibb Company is up $1.49 (3.0%) to $51.29 on average volume. Thus far, 5.8 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.6 million shares. The stock has ranged in price between $49.83-$51.34 after having opened the day at $49.92 as compared to the previous trading day's close of $49.80.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $81.9 billion and is part of the health care sector. Shares are down 6.3% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is up $1.12 (1.9%) to $59.09 on average volume. Thus far, 5.4 million shares of Merck exchanged hands as compared to its average daily volume of 9.0 million shares. The stock has ranged in price between $58.14-$59.20 after having opened the day at $58.82 as compared to the previous trading day's close of $57.97.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $169.9 billion and is part of the health care sector. Shares are up 15.8% year-to-date as of the close of trading on Monday. Currently there are 6 analysts who rate Merck a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Merck Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Gilead ( GILD) is up $1.28 (1.4%) to $92.74 on average volume. Thus far, 8.0 million shares of Gilead exchanged hands as compared to its average daily volume of 11.8 million shares. The stock has ranged in price between $91.60-$93.10 after having opened the day at $92.10 as compared to the previous trading day's close of $91.46.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $138.0 billion and is part of the health care sector. Shares are up 21.8% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing